Status: Recruiting
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
Participants needed: 49
Trial details
Phase: Phase 1, Phase 2Age: 20+Biological sex: AllType: InterventionalSponsor: National Health Research Institutes, TaiwanUpdated: Apr 9, 2026Locations: 11
Eligibility criteria
Pathologically confirmed G1 or G2 NET of GEP origin with locally advanced or met... [+21]
Prior use of cabozantinib. (prior use of lanreotide is acceptable) [+25]